MacroGenics to Sell Margenza Cancer Drug for $40 Million

By MarketWatch | Oct 22, 2024 at 07:53 AM EST

MacroGenics will sell the rights to its Margenza breast-cancer drug to TerSera Therapeutics for $40 million, with potential for $35 million in milestone payments. This deal allows MacroGenics to focus on its oncology pipeline as Margenza struggles to generate profit.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.